share_log

Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Point72 Asset Management, L.P.(0.2%),Point72 Capital Advisors, Inc.(0.2%), etc.

Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Point72 Asset Management, L.P.(0.2%),Point72 Capital Advisors, Inc.(0.2%), etc.

Arcutis Biotherapeutics | SC 13G/A：超过5%持股股东披露文件(修正)-Point72 Asset Management, L.P.(0.2%),Point72 Capital Advisors, Inc.(0.2%)等
美股SEC公告 ·  11/15 11:57

Moomoo AI 已提取核心信息

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13G/A filing with the Securities and Exchange Commission (SEC) on September 30, 2024, indicating a change in ownership by several related investment entities. Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., Cubist Systematic Strategies, LLC, and Steven A. Cohen collectively reported shared voting and dispositive power over 247,055 shares of Arcutis Biotherapeutics, representing 0.2% of the company's class of common stock. The filing, signed by authorized person Jason M. Colombo, clarifies that none of the reporting persons directly own shares but have investment and voting power through managed funds. The address for Point72 Asset Management, Point72 Capital Advisors, and Mr. Cohen is in Stamford, CT, while Cubist Systematic Strategies is located in New York, NY. All entities are organized under Delaware law, with Mr. Cohen being a U.S. citizen. The filing also indicates that the reporting persons do not have an intention to change or influence the control of Arcutis Biotherapeutics.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13G/A filing with the Securities and Exchange Commission (SEC) on September 30, 2024, indicating a change in ownership by several related investment entities. Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., Cubist Systematic Strategies, LLC, and Steven A. Cohen collectively reported shared voting and dispositive power over 247,055 shares of Arcutis Biotherapeutics, representing 0.2% of the company's class of common stock. The filing, signed by authorized person Jason M. Colombo, clarifies that none of the reporting persons directly own shares but have investment and voting power through managed funds. The address for Point72 Asset Management, Point72 Capital Advisors, and Mr. Cohen is in Stamford, CT, while Cubist Systematic Strategies is located in New York, NY. All entities are organized under Delaware law, with Mr. Cohen being a U.S. citizen. The filing also indicates that the reporting persons do not have an intention to change or influence the control of Arcutis Biotherapeutics.
Arcutis biotherapeutics公司是一家生物制药公司，于2024年9月30日向证券交易委员会（SEC）提交了Schedule 13G/A文件，表明几个相关投资实体的所有权发生了变化。Point72 资产管理公司、Point72 资本顾问公司、Cubist 系统策略公司和Steven A. cohen共同报告对247,055股Arcutis biotherapeutics的股份拥有投票权和处置权，占该公司普通股类别的0.2%。该文件由授权人Jason m. Colombo签署，明确表示报告人没有直接拥有股份，但通过管理的所有基金类型拥有投资和投票权。Point72 资产管理公司、...展开全部
Arcutis biotherapeutics公司是一家生物制药公司，于2024年9月30日向证券交易委员会（SEC）提交了Schedule 13G/A文件，表明几个相关投资实体的所有权发生了变化。Point72 资产管理公司、Point72 资本顾问公司、Cubist 系统策略公司和Steven A. cohen共同报告对247,055股Arcutis biotherapeutics的股份拥有投票权和处置权，占该公司普通股类别的0.2%。该文件由授权人Jason m. Colombo签署，明确表示报告人没有直接拥有股份，但通过管理的所有基金类型拥有投资和投票权。Point72 资产管理公司、Point72 资本顾问公司和cohen先生的地址位于康涅狄格州斯坦福，而Cubist 系统策略公司位于纽约州纽约市。所有实体均按特拉华州法律组织，cohen先生为美国公民。文件还表明，报告人并无意改变或影响Arcutis biotherapeutics的控制权。

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间